Xyzal gains expanded pediatric indication

XYZAL (levocetirizine) 0.5mg/mL oral solution by UCB and Sanofi Aventis
XYZAL (levocetirizine) 0.5mg/mL oral solution by UCB and Sanofi Aventis
The FDA has approved an expanded pediatric indication for Xyzal (levocetirizine dihydrochloride, from UCB and Sanofi-aventis) to include the relief of symptoms associated with perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children ≥6 months of age. Xyzal has also been approved for the relief of symptoms associated with seasonal allergic rhinitis in children ≥2 years of age.

Xyzal tablets and Xyzal oral solution are already indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and for the treatment of chronic idiopathic urticaria in adults and children ≥6 years of age.

For more information call (888) NOW-XYZAL or visit www.xyzal.com.